Phase 1 results of a phase 1/2 trial of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination, in patients with advanced solid and hematologic cancers. Lynch, R. C., Munster, P. N., Advani, R. H., Hamadani, M., Spigel, D. R., Falchook, G., Patel, M. R., Siegel, D., Beri, N., Nowakowski, G. S., Palmisiano, N., Burness, M., Moore, K. N., Shapiro, G., Juric, D., Bradley, W. D., O'Shea, T. J., Renschler, M., Englert, J. M., Yap, T. A. LIPPINCOTT WILLIAMS & WILKINS. 2022

View details for Web of Science ID 000863680300977